|
|
| (299 intermediate revisions by 3 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | [[Syncope]] is classified into three types: |
| == Diagnosis ==
| | * [[Cardiac]] |
| ===Diagnostic Criteria===
| | * [[Neurogenic]] |
| In May 2020, the Centers for Disease Control and Prevention (CDC) set the criteria for multisystem inflammatory syndrome in children (MIS-C):<ref name="FeldsteinRose2020">{{cite journal|last1=Feldstein|first1=Leora R.|last2=Rose|first2=Erica B.|last3=Horwitz|first3=Steven M.|last4=Collins|first4=Jennifer P.|last5=Newhams|first5=Margaret M.|last6=Son|first6=Mary Beth F.|last7=Newburger|first7=Jane W.|last8=Kleinman|first8=Lawrence C.|last9=Heidemann|first9=Sabrina M.|last10=Martin|first10=Amarilis A.|last11=Singh|first11=Aalok R.|last12=Li|first12=Simon|last13=Tarquinio|first13=Keiko M.|last14=Jaggi|first14=Preeti|last15=Oster|first15=Matthew E.|last16=Zackai|first16=Sheemon P.|last17=Gillen|first17=Jennifer|last18=Ratner|first18=Adam J.|last19=Walsh|first19=Rowan F.|last20=Fitzgerald|first20=Julie C.|last21=Keenaghan|first21=Michael A.|last22=Alharash|first22=Hussam|last23=Doymaz|first23=Sule|last24=Clouser|first24=Katharine N.|last25=Giuliano|first25=John S.|last26=Gupta|first26=Anjali|last27=Parker|first27=Robert M.|last28=Maddux|first28=Aline B.|last29=Havalad|first29=Vinod|last30=Ramsingh|first30=Stacy|last31=Bukulmez|first31=Hulya|last32=Bradford|first32=Tamara T.|last33=Smith|first33=Lincoln S.|last34=Tenforde|first34=Mark W.|last35=Carroll|first35=Christopher L.|last36=Riggs|first36=Becky J.|last37=Gertz|first37=Shira J.|last38=Daube|first38=Ariel|last39=Lansell|first39=Amanda|last40=Coronado Munoz|first40=Alvaro|last41=Hobbs|first41=Charlotte V.|last42=Marohn|first42=Kimberly L.|last43=Halasa|first43=Natasha B.|last44=Patel|first44=Manish M.|last45=Randolph|first45=Adrienne G.|title=Multisystem Inflammatory Syndrome in U.S. Children and Adolescents|journal=New England Journal of Medicine|year=2020|issn=0028-4793|doi=10.1056/NEJMoa2021680}}</ref>
| | * [[Vasovagal syncope|vasovagal]] |
| | |
| * Severe disease course leading to hospitalization
| |
| * Individuals younger than 21 years old
| |
| * Fever (body temperature, >38.0°C) or report of subjective fever present at least 24 hours
| |
| * Laboratory evidence of inflammation
| |
| * Multisystem organ involvement (at least two systems)
| |
| * Laboratory-confirmed SARS-CoV-2 infection
| |
| | |
| === History and Symptoms ===
| |
| | |
| *[[Fever]] lasting 24 hours or longer.
| |
| *[[Vomiting]]
| |
| *[[Diarrhea]]
| |
| *[[Abdominal pain]]
| |
| *[[Shortness of breath|Difficulty Breathing]]
| |
| *[[Chest pain]]
| |
| *[[Headache]]
| |
| *[[Sore throat]]
| |
| *[[Confusion|New onset confusion]]
| |
| | |
| ===Physical Examination===
| |
| *[[Skin rash]] | |
| *[[Conjuctivitis]]
| |
| *Redness or swelling of the lips and tongue
| |
| *[[Redness]] or swelling of the hands or feet
| |
| *[[Lymphadenopathy]]
| |
| *[[Lethargy]]
| |
| *[[Cyanosis]]
| |
| ===Laboratory Findings===
| |
| *[[Erythrocyte sedimentation rate|High ESR]]
| |
| '''Blood Investigations'''
| |
| *[[Lymphopenia]], [[Neutrophilia]], [[Anemia]], [[Thrombocytopenia]] have been seen in MIS-C pateints. [[Fibrinogen|Abnormal fibrinogen]], [[Hypoalbuminaemia]], elevated [[Creatine kinase|creatiine kinase]] (CK), [[Lactate dehydrogenase|LDH]], [[Triglyceride|triglycerides]] have been observed in MIS-C patients.
| |
| ==== Inflammatory biomarkers ====
| |
| Elevation of inflammatory markers including ESR, C reactive protein, and procalcitonin are usually seen in MIS-C. Increased level of [[Interleukin-6]] (IL-6), Interleukin-10(IL-10) [[d-dimer]], serum [[ferritin]], [[prothrombin time]] have also been seen in MIS-C.
| |
| ==== Cardiac biomarkers ====
| |
| Elevation of cardic enzymes including [[Cardiac troponin|cardiac troponins]] ([[Cardiac troponin I (cTnI) and T (cTnT)|cardiac troponin I(cTnI) and cardiac troponin T (cTnT)]]) and [[Brain natriuretic peptide]] ([[BNP]])) has been observed in MIS-C patients.
| |
| | |
| === Radiological Findings ===
| |
| | |
| * Following Radiological Findings are observed in MIS-C patients.
| |
| | |
| {| border="1" cellpadding="2"
| |
| ! width="225" |Test
| |
| ! width="225" |Findings
| |
| |-
| |
| |Chest Xray||patchy symmetrical infiltrates, [[pleural effusion]]
| |
| |-
| |
| |Echocardiogram and EKG||[[myocarditis]], valvulitis, [[pericardial effusion]], coronary artery dilatation
| |
| |-
| |
| |Abdominal USG||[[colitis]], [[ileitis]], [[lymphadenopathy]], [[ascites]], [[hepatosplenomegaly]]
| |
| |}
| |
| '''Blood Culture, Viral PCR'''
| |
| | |
| * Absence of other potential causative organisms. IgG levels and IgM levels of [[SARS-CoV-2]] are detected.
| |
| | |
| == Treatment ==
| |
| === Medical Therapy ===
| |
| | |
| *All the children with MIS-C are treated as suspected [[COVID-19|COVID-19.]]
| |
| *Mild to Moderate cases of MIS-C are managed supportively.<ref name="A1"">{{Cite web|url=https://www.chop.edu/clinical-pathway/multisystem-inflammatory-syndrome-mis-c-clinical-pathway|title=Emergency Department, ICU and Inpatient Clinical Pathway for
| |
| Evaluation of Possible Multisystem Inflammatory Syndrome (MIS-C)|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref><ref name="A2">{{Cite web|url=https://www.chkd.org/uploadedFiles/Documents/COVID-19/CHKD%20MIS-C%20Guideline%20D2.pdf|title= Evaluation and Management of COVID-19 Multisystem Inflammatory
| |
| Syndrome in Children (MIS-C)|last=|first=|date=|website=|archive-url=|archive-date=|dead-url=|access-date=}}</ref>
| |
| *Supplemental [[oxygen]] is required in children with low oxygen saturation.<ref name="A2"/>
| |
| *[[Fluid replacement|Fluid resuscitation]] in 10 ml/kg aliquots with reevaluation after each bolus. Maintain euvolemia. Avoid hypervolemia.<ref name="A2"/>
| |
| *Anti-inflammatory treatments with [[Intravenous immunoglobulin|Intravenous immunoglobulin(IVIG]]) with or without [[Corticosteroid|corticosteroids]] have shown a good response rate.<ref name="A1""/><ref name="A2"/>
| |
| *[[Aspirin]] has been used primarily for its antiplatelet effect. It is recommended in all patients with [[MIS-C]].<ref name="A1""/><ref name="A2"/>
| |
| *[[Anakinra]] is considered if fevers last more than 24 hours post [[Steroid|steroids]]/[[Intravenous immunoglobulin|IVIG]] or in the moderate or severe presentation.<ref name="A1""/><ref name="A2"/>
| |
| *[[Tocilizumab]] is also considered if fevers last more than 24 hours post steroids/IVIG or in the moderate or severe presentation.<ref name="A1""/><ref name="A2"/>
| |
| *Empiric antibiotics like [[vancomycin]], [[ceftriaxone]], and [[clindamycin]] are given for community-acquired shock presentation until cultures are negative for 48 hours.<ref name="A1""/><ref name="A2"/>
| |
| | |
| {| border="1" cellpadding="2"
| |
| ! width="225" |Presentation
| |
| ! width="225" |Treatment
| |
| |-
| |
| |Mild Disease||
| |
| *Symptomatic Treatment
| |
| |-
| |
| |Severe Disease||
| |
| *Symptomatic Treatment
| |
| *[[Intravenous immunoglobulin|IVIG(IV)]]
| |
| *[[Corticosteroid|Corticosteroids]](IV/PO) | |
| *Consider adding [[Anakinra]] or [[Tocilizumab]] if [[fever]] persist for more than 24 hours post [[Steroid|steroids]] and I[[Intravenous immunoglobulin|VIG]] use. | |
| |}
| |
| | |
| == Prevention of MIS-C ==
| |
| | |
| *MIS-C can be prevented by reducing the risk of child exposure to [[COVID-19|COVID]]-19 infection.
| |
| | |
| == References ==
| |
| {{Reflist|2}}
| |
| | |
| | |
| | |
| | |
| '''Bold text'''
| |
| {| class="wikitable"
| |
| ! colspan="10" style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Wikidoc Textbook of Medicine}}
| |
| |-
| |
| ! style="background: #4479BA; width: 150px;" |{{fontcolor|#FFF| Name/Project}}
| |
| ! style="background: #4479BA; width: 150px;" |{{fontcolor|#FFF| Cardiology}}
| |
| ! style="background: #4479BA; width: 150px;" |{{fontcolor|#FFF| Pulmonary}}
| |
| ! style="background: #4479BA; width: 150px;" |{{fontcolor|#FFF| Infectious}}
| |
| ! style="background: #4479BA; width: 150px;" |{{fontcolor|#FFF| Pediatrics}}
| |
| ! style="background: #4479BA; width: 150px;" |{{fontcolor|#FFF| Emergency}}
| |
| ! style="background: #4479BA; width: 150px;" |{{fontcolor|#FFF| ENT}}
| |
| ! style="background: #4479BA; width: 150px;" |{{fontcolor|#FFF| Ob/Gyn}}
| |
| ! style="background: #4479BA; width: 150px;" |{{fontcolor|#FFF| Dermatology}}
| |
| ! style="background: #4479BA; width: 150px;" |{{fontcolor|#FFF| Rare disease}}
| |
| |-
| |
| |Leader of the Project
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |N of Chapters
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |N of Complete Chapters
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |N of Incomplete Chapters
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |N to be Reviewed
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| ! colspan="10" style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|'''Name of Scholars working on the project'''}}
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |}
| |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| {| class="wikitable"
| |
| |+
| |
| ! colspan="8" style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Wikidoc Textbook of Medicine}}
| |
| |-
| |
| ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Name/Project}}
| |
| ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Hematology}}
| |
| ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Oncology}}
| |
| ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Gastroenterology}}
| |
| ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Nephrology}}
| |
| ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Neurology}}
| |
| ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Psychology}}
| |
| ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Endocrinology}}
| |
| |-
| |
| |Leader of the project
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |N of Chapters
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |N of complete Chapters
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |N of Incomplete Chapters
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |N to be reviewed Chapters
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| ! colspan="8" style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|'''Name of Scholars working on the project'''}}
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |}
| |
| | |
| | |
| | |
| {| border="3"
| |
| |+
| |
| ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Disease Name}}
| |
| ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Age of Onset}}
| |
| ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Gender Preponderance}}
| |
| ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Signs/Symptoms}}
| |
| ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Imaging Feature(s)}}
| |
| ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Macroscopic Feature(s)}}
| |
| ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Microscopic Feature(s)}}
| |
| ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Laboratory Findings(s)}}
| |
| ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| Other Feature(s)}}
| |
| ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF| ECG view}}
| |
| |-
| |
| ! style="padding: 5px 5px; background: #DCDCDC; " align="left"|
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| |-
| |
| ! style="padding: 5px 5px; background: #DCDCDC; " align="left"|
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| |-
| |
| ! style="padding: 5px 5px; background: #DCDCDC;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| |-
| |
| ! style="padding: 5px 5px; background: #DCDCDC;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| |-
| |
| ! style="padding: 5px 5px; background: #DCDCDC;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| |-
| |
| ! style="padding: 5px 5px; background: #DCDCDC;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| |-
| |
| ! style="padding: 5px 5px; background: #DCDCDC; " align="left" |
| |
| | |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| | style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| |
| |-
| |
| ! style="padding: 5px 5px; background: #DCDCDC; " align="left"|
| |
| !
| |
| !
| |
| !
| |
| !
| |
| !
| |
| !
| |
| !
| |
| !
| |
| !
| |
| |-
| |
| !
| |
| !
| |
| !
| |
| !
| |
| !
| |
| !
| |
| !
| |
| !
| |
| !
| |
| !
| |
| |}
| |
| <references />
| |